SG11202110888QA - Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors - Google Patents
Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitorsInfo
- Publication number
- SG11202110888QA SG11202110888QA SG11202110888QA SG11202110888QA SG11202110888QA SG 11202110888Q A SG11202110888Q A SG 11202110888QA SG 11202110888Q A SG11202110888Q A SG 11202110888QA SG 11202110888Q A SG11202110888Q A SG 11202110888QA SG 11202110888Q A SG11202110888Q A SG 11202110888QA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- bicyclic heteroaryl
- heteroaryl derivatives
- ectonucleotide pyrophosphatase
- pyrophosphatase phosphodiesterase
- Prior art date
Links
- 108010067341 ectonucleotide pyrophosphatase phosphodiesterase 1 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
- C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833455P | 2019-04-12 | 2019-04-12 | |
| US201962881111P | 2019-07-31 | 2019-07-31 | |
| PCT/US2020/027700 WO2020210649A1 (en) | 2019-04-12 | 2020-04-10 | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202110888QA true SG11202110888QA (en) | 2021-10-28 |
Family
ID=70465561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202110888QA SG11202110888QA (en) | 2019-04-12 | 2020-04-10 | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20220362266A1 (en) |
| EP (2) | EP3952995B1 (en) |
| JP (1) | JP2022526432A (en) |
| KR (1) | KR20210151873A (en) |
| CN (1) | CN114040915A (en) |
| AU (1) | AU2020272034A1 (en) |
| BR (1) | BR112021020241A2 (en) |
| CA (1) | CA3136443A1 (en) |
| DK (1) | DK3952995T3 (en) |
| ES (1) | ES2960987T3 (en) |
| FI (1) | FI3952995T3 (en) |
| HR (1) | HRP20231413T1 (en) |
| HU (1) | HUE064377T2 (en) |
| IL (1) | IL286966A (en) |
| LT (1) | LT3952995T (en) |
| MX (2) | MX2021012305A (en) |
| PL (1) | PL3952995T3 (en) |
| PT (1) | PT3952995T (en) |
| RS (1) | RS64792B1 (en) |
| SG (1) | SG11202110888QA (en) |
| SI (1) | SI3952995T1 (en) |
| TW (1) | TW202103708A (en) |
| WO (1) | WO2020210649A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3204409A1 (en) * | 2021-01-29 | 2022-08-04 | Chan Sun Park | Novel benzotriazole derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase, and use thereof |
| WO2022197734A1 (en) * | 2021-03-16 | 2022-09-22 | Riboscience Llc | Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
| CN116444544A (en) * | 2022-01-10 | 2023-07-18 | 中国科学院上海药物研究所 | Benzimidazole compound and medical application thereof |
| WO2024099907A1 (en) * | 2022-11-09 | 2024-05-16 | Boehringer Ingelheim International Gmbh | Cyclic benzimidazole derivatives as cgas inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| DK40192D0 (en) * | 1992-03-26 | 1992-03-26 | Neurosearch As | IMIDAZOLE COMPOUNDS, THEIR PREPARATION AND USE |
| US20090176849A1 (en) * | 2005-05-24 | 2009-07-09 | Lek Pharmaceuticals, D.D. | Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) Methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives |
| CN100427488C (en) * | 2005-10-21 | 2008-10-22 | 上海东升新材料有限公司 | Adenine kind derivative and its synthesis method |
| JO3598B1 (en) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | Boronic acids and esters as inhibitors of fatty acid amide hydrolase |
| EP3246034A1 (en) * | 2008-03-06 | 2017-11-22 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-inflammatory agents |
| EP2558577B1 (en) * | 2010-04-16 | 2018-12-12 | Nuevolution A/S | Bi-functional complexes and methods for making and using such complexes |
| EP2710006A1 (en) * | 2011-05-17 | 2014-03-26 | Principia Biopharma Inc. | Azaindole derivatives as tyrosine kinase inhibitors |
| WO2016055582A1 (en) * | 2014-10-08 | 2016-04-14 | Thomas Helledays Stiftelse För Medicinsk Forskning | Heterocyclic compounds as dctpp1 modulators |
| ES2823049T3 (en) * | 2015-07-31 | 2021-05-05 | Pfizer | 1,1,1-Trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors |
| CN110446503A (en) * | 2016-12-22 | 2019-11-12 | 马福制药公司 | Phosphodiesterase inhibitors and antimicrobial treatments method |
| CA3047579A1 (en) * | 2016-12-22 | 2018-06-28 | Mavupharma, Inc. | Compositions and methods of enhancing or augmenting type i ifn production |
| US10487084B2 (en) * | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| WO2019096113A1 (en) * | 2017-11-14 | 2019-05-23 | 深圳市塔吉瑞生物医药有限公司 | Deuterium-substituted boron-containing compound, and pharmaceutical composition and use |
-
2020
- 2020-04-10 TW TW109112260A patent/TW202103708A/en unknown
- 2020-04-10 SG SG11202110888QA patent/SG11202110888QA/en unknown
- 2020-04-10 LT LTEPPCT/US2020/027700T patent/LT3952995T/en unknown
- 2020-04-10 ES ES20722196T patent/ES2960987T3/en active Active
- 2020-04-10 CN CN202080028332.4A patent/CN114040915A/en active Pending
- 2020-04-10 SI SI202030281T patent/SI3952995T1/en unknown
- 2020-04-10 JP JP2021559932A patent/JP2022526432A/en active Pending
- 2020-04-10 HU HUE20722196A patent/HUE064377T2/en unknown
- 2020-04-10 DK DK20722196.1T patent/DK3952995T3/en active
- 2020-04-10 HR HRP20231413TT patent/HRP20231413T1/en unknown
- 2020-04-10 RS RS20231040A patent/RS64792B1/en unknown
- 2020-04-10 US US17/264,684 patent/US20220362266A1/en active Pending
- 2020-04-10 EP EP20722196.1A patent/EP3952995B1/en active Active
- 2020-04-10 BR BR112021020241A patent/BR112021020241A2/en unknown
- 2020-04-10 EP EP23187601.2A patent/EP4249070A3/en active Pending
- 2020-04-10 PL PL20722196.1T patent/PL3952995T3/en unknown
- 2020-04-10 PT PT207221961T patent/PT3952995T/en unknown
- 2020-04-10 AU AU2020272034A patent/AU2020272034A1/en active Pending
- 2020-04-10 WO PCT/US2020/027700 patent/WO2020210649A1/en active Application Filing
- 2020-04-10 CA CA3136443A patent/CA3136443A1/en active Pending
- 2020-04-10 KR KR1020217036122A patent/KR20210151873A/en unknown
- 2020-04-10 FI FIEP20722196.1T patent/FI3952995T3/en active
- 2020-04-10 MX MX2021012305A patent/MX2021012305A/en unknown
-
2021
- 2021-10-04 IL IL286966A patent/IL286966A/en unknown
- 2021-10-07 MX MX2023011065A patent/MX2023011065A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023011065A (en) | 2023-09-28 |
| CA3136443A1 (en) | 2020-10-15 |
| RS64792B1 (en) | 2023-11-30 |
| EP4249070A2 (en) | 2023-09-27 |
| ES2960987T3 (en) | 2024-03-07 |
| KR20210151873A (en) | 2021-12-14 |
| EP3952995B1 (en) | 2023-09-20 |
| US20220362266A1 (en) | 2022-11-17 |
| FI3952995T3 (en) | 2023-10-26 |
| EP4249070A3 (en) | 2024-04-17 |
| WO2020210649A1 (en) | 2020-10-15 |
| DK3952995T3 (en) | 2023-10-30 |
| JP2022526432A (en) | 2022-05-24 |
| TW202103708A (en) | 2021-02-01 |
| HUE064377T2 (en) | 2024-03-28 |
| EP3952995A1 (en) | 2022-02-16 |
| MX2021012305A (en) | 2021-11-12 |
| AU2020272034A1 (en) | 2021-10-28 |
| PT3952995T (en) | 2023-10-25 |
| LT3952995T (en) | 2023-11-10 |
| SI3952995T1 (en) | 2023-12-29 |
| HRP20231413T1 (en) | 2024-02-16 |
| CN114040915A (en) | 2022-02-11 |
| PL3952995T3 (en) | 2024-03-11 |
| BR112021020241A2 (en) | 2021-12-07 |
| IL286966A (en) | 2021-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286966A (en) | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | |
| IL276509A (en) | Heterocyclic compounds as kinase inhibitors | |
| EP3902787A4 (en) | Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | |
| SI3523301T1 (en) | Substituted pyrazolo(1,5-a)pyridine compounds as ret kinase inhibitors | |
| IL290508A (en) | Heterocyclic compounds as kinase inhibitors | |
| SG11202011299PA (en) | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | |
| EP4067359A4 (en) | Pyrimidoimidazole compounds used as dna-pk inhibitors | |
| SG11202013016YA (en) | Heterocyclic compounds as trk inhibitors | |
| EP3666770A4 (en) | Novel heterocyclic compounds as cdk8/19 inhibitors | |
| IL273443A (en) | Bicyclic compounds for use as rip1 kinase inhibitors | |
| IL284767A (en) | Heterocyclic compounds as adenosine antagonists | |
| SG11202109781QA (en) | Uses of phosphodiesterase inhibitors | |
| IL289389A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL284762A (en) | Heterocyclic compounds as adenosine antagonists | |
| SG11202008705TA (en) | Heteroaryl compounds as kinase inhibitor | |
| SG10202110112TA (en) | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors | |
| EP3844166C0 (en) | Substituted macrocycles useful as kinase inhibitors | |
| IL291785A (en) | Substituted 1, 6-naphthyridine inhibitors of cdk5 | |
| SG11202102015QA (en) | Fused ring derivative used as fgfr4 inhibitor | |
| EA201692227A1 (en) | DERIVATIVES OF COMPLEX AMINOESTERS | |
| IL269144A (en) | Pyrrolotriazine derivatives as kinase inhibitor | |
| IL290314A (en) | Quinoline derivatives as protein kinase inhibitors | |
| ZA201908372B (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
| IL291382A (en) | 2-amino-s6-substituted thiopurine compounds as inhibitors of the enpp1 protein | |
| EP3863638A4 (en) | Phosphodiesterase inhibitors |